Insulet slides as investors weigh Omnipod 5 device correction and potential 2026 costs

Insulet Corporation (PODD) is down 4.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The decline likely reflects continued investor focus on Insulet’s recently disclosed voluntary medical device correction involving certain Omnipod 5 Pod lots in the U.S. Even with management indicating limited scope and no change to prior 2026 guidance, the combination of patient-safety optics and expected remediation costs can pressure sentiment in the near term.

Details:

Insulet disclosed a voluntary medical device correction for specific lots of Omnipod 5 Pods after identifying a manufacturing issue involving a potential tear in internal tubing, which may lead to insulin leakage and under-delivery.

The company said under-delivery can result in high blood glucose and, in severe cases, diabetic ketoacidosis; it also stated it has received 18 reports of serious adverse events tied to high blood glucose, including hospitalization and DKA, with no deaths reported.

Insulet indicated the impacted Pods represent about 1.5% of annual Omnipod 5 pod production globally and said it does not anticipate disruption to shipments, product availability, or new patient starts.

In a related Form 8-K disclosure, Insulet said it currently expects up to $40 million of costs associated with the event in 2026 (excluded from adjusted results) and said it is not changing previously issued 2026 guidance as a result of the voluntary action.

Sources:

U.S. SEC (EDGAR), Insulet Investor Relations, Y94

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$PODD Insider Trading Activity

$PODD insiders have traded $PODD stock on the open market 4 times in the past 6 months. Of those trades, 3 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $PODD stock by insiders over the last 6 months:

ASHLEY MCEVOY (President and CEO) purchased 4,300 shares for an estimated $1,029,205
WAYNE A.I. FREDERICK sold 1,851 shares for an estimated $542,509
MICHAEL R MINOGUE purchased 2,030 shares for an estimated $499,846
TIMOTHY C. STONESIFER purchased 962 shares for an estimated $299,884

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$PODD Hedge Fund Activity

We have seen 418 institutional investors add shares of $PODD stock to their portfolio, and 425 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 2,299,597 shares (-74.0%) from their portfolio in Q4 2025, for an estimated $653,637,451
FMR LLC removed 1,244,468 shares (-16.4%) from their portfolio in Q4 2025, for an estimated $353,727,584
MACQUARIE GROUP LTD removed 474,325 shares (-98.7%) from their portfolio in Q4 2025, for an estimated $134,822,138
VOYA INVESTMENT MANAGEMENT LLC added 337,421 shares (+531.8%) to their portfolio in Q4 2025, for an estimated $95,908,545
RTW INVESTMENTS, LP added 324,600 shares (+inf%) to their portfolio in Q4 2025, for an estimated $92,264,304
AQR CAPITAL MANAGEMENT LLC added 283,643 shares (+161.6%) to their portfolio in Q4 2025, for an estimated $80,622,686
BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. added 258,775 shares (+inf%) to their portfolio in Q4 2025, for an estimated $73,554,206

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$PODD Analyst Ratings

Wall Street analysts have issued reports on $PODD in the last several months. We have seen 8 firms issue buy ratings on the stock, and 1 firms issue sell ratings.

Here are some recent analyst ratings:

Barclays issued a "Underweight" rating on 01/12/2026
Truist Securities issued a "Buy" rating on 12/18/2025
Canaccord Genuity issued a "Buy" rating on 11/24/2025
BTIG issued a "Buy" rating on 11/21/2025
RBC Capital issued a "Outperform" rating on 11/21/2025
UBS issued a "Buy" rating on 11/19/2025
Wells Fargo issued a "Overweight" rating on 11/07/2025

To track analyst ratings and price targets for $PODD, check out Quiver Quantitative's $PODD forecast page.

$PODD Price Targets

Multiple analysts have issued price targets for $PODD recently. We have seen 18 analysts offer price targets for $PODD in the last 6 months, with a median target of $357.5.

Here are some recent targets:

Joanne Wuensch from Citigroup set a target price of $338.0 on 03/11/2026
Robbie Marcus from JP Morgan set a target price of $340.0 on 02/19/2026
William Plovanic from Canaccord Genuity set a target price of $435.0 on 02/19/2026
Suraj Kalia from Oppenheimer set a target price of $300.0 on 02/19/2026
Lee Hambright from Bernstein set a target price of $330.0 on 02/19/2026
David Roman from Goldman Sachs set a target price of $326.0 on 02/19/2026
Richard Newitter from Truist Securities set a target price of $360.0 on 02/19/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.